Emerging evidence, from our study and beyond, reinforces the potential of the RANKL-blocking antibody denosumab, not only for its bone-protective properties in late-stage myeloma, but also for its potential anti-myeloma effects. Here, TNFSF11 is linked to plasma cell myeloma.